Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Three...

    Three healthcare-focused funds keen to pick minority stake in Morpheus IVF

    Written by Ruby Khatun Khatun Published On 2017-08-14T09:25:18+05:30  |  Updated On 16 Aug 2021 12:24 PM IST

    MUMBAI: Morpheus IVF wants to sell a minority stake for which it has attracted the interest of major healthcare-focused funds Quadria Capital, Asian Healthcare Fund and Tata Healthcare Fund. The promoters of Morpheus IVF want to sell a significant minority stake for around $15 million, a latest report in Economic Times.


    Morpheus was Founded in 2009 in Mumbai in the partnership with IVF International, a German company as the primary promoter. It has the 30-plus chain of centers working on a partnership model where it financially partners with local specialists whereby leveraging on their individual brand and sharing the set-up cost.


    According to a report in The Economic Times quoting sources, the company is looking to raise growth capital for opening up new centers for which the company has appointed investment bank 7i Capital to look for buyers.


    Speaking with Economic Times a person said, "Unlike its many peers, the company has managed to keep its business model asset light where Capex requirement is low."


    The IVF market in India is at emerging stage which is growing at 20 per cent annually. The Rs 1,000-crore market sees around 1 lakh embryo transfer cycles annually with the average cost Rs 1 lakh for each transfer cycle.


    Speaking about the development, a source told ET "The increasing customer awareness and the changing lifestyle leading to fertility related issues in new-age couples is going to aid the growth of the sector going forward."

    7i CapitalAsian Healthcare Fundcapexembryo transfer cycleshealthcare-focused fundsinvestment bankIVFIVF Internationalmarketminority stakeMorpheus IVFpickQuadria CapitalTata Healthcare Fund
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok